Smac mimetic compounds (SMCs) are experimental small molecules that induce tumour necrosis factor alpha (TNFa)-dependent cancer cell death by targeting the inhibitor of apoptosis proteins. However, many cancer cell lines are resistant to SMC-mediated apoptosis despite the presence of TNFa. To add insight into the mechanism of SMC-resistance, we used functional siRNA-based kinomic and focused chemical screens and identified suppressor of morphogenesis in genitalia-1 (SMG1) and NF-jB-inducing kinase (NIK) as novel protective factors. Both SMG1 and NIK prevent SMC-mediated apoptosis likely by maintaining FLICE inhibitory protein (c-FLIP) levels to suppress caspase-8 activation. In SMC-resistant cells, the accumulation of NIK upon SMC treatment enhanced the activity of both the classical and alternative nuclear factor-jB pathways, and increased c-FLIP mRNA levels. In parallel, persistent SMG1 expression in SMC-resistant cells repressed SMC-mediated TNFa-induced JNK activation and c-FLIP levels were sustained. Importantly, SMC-resistance is overcome by depleting NIK and SMG1, which appear to facilitate the downregulation of c-FLIP in response to SMC and TNFa treatment, leading to caspase-8-dependent apoptosis. Collectively, these data show that SMG1 and NIK function as critical repressors of SMC-mediated apoptosis by potentially converging on the regulation of c-FLIP metabolism.
The inhibitor of apoptosis (IAP) proteins are key repressors of programmed cell death. Evasion from apoptosis is a hallmark of tumourigenesis, 1 and consequently, the IAPs have become important targets for the development of anticancer therapies. 2 Current approaches that are under clinical development for the targeting of the IAPs include antisense oligonucleotides that repress IAP gene expression and synthetic small molecules that antagonize IAP function. 3 The suppression of apoptosis by the IAPs is primarily mediated through the inhibition of caspase activity, either directly via their baculoviral IAP repeat (BIR) domains or indirectly through their ubiquitin E3 ligase RING domain. The ability of the BIR2 domain of X-linked IAP (XIAP) to bind and inhibit the effector caspases-3 and -7, and the ability of the BIR3 domain of XIAP to function as a direct inhibitor for the initiator caspase-9, have been extensively documented. 4, 5 As well, recent evidence indicates that the ubiquitin E3 ligase RING domain of cellular IAP1 (cIAP1) and cellular IAP2 (cIAP2) can indirectly inhibit apoptosis by modulating the ubiquitination status of the kinase receptor-interacting protein 1 (RIP1). [6] [7] [8] In response to tumour necrosis factor alpha (TNFa), cIAP1 or cIAP2 facilitates the ubiquitination of RIP1 and thereby blocks the recruitment of caspase-8 and FADD to RIP1, preventing the formation of the death-inducing complex II. 9, 10 The indirect inhibition of caspase-8 by cIAP1
and cIAP2 is indispensable for the prevention of TNFamediated apoptosis. Smac mimetic compounds (SMCs) are small molecule therapeutics that target the IAPs and are currently in clinical trials for cancer. 3 The structure of SMCs were rationally designed from a conserved IAP-binding motif that contains the AVPI tetrapeptide amino terminal sequence of Smac, which binds to the BIR2 and BIR3 domains of cIAP1, cIAP2 and XIAP. [11] [12] [13] The mode of action for SMCs in sensitive cancer cells involves the rapid activation of the ubiquitin E3 ligase of cIAP1 and cIAP2, leading to autoubiquitination and proteasomal degradation of these cIAPs. 6, [14] [15] [16] [17] In the absence of the cIAPs, RIP1 ubiquitination is markedly reduced, [6] [7] [8] thereby sensitizing cancer cells to TNFamediated apoptosis via the preferential formation of the death-inducing complex II.
Resistance to SMC treatment has been shown in diverse cancer cell lines 9, 18 and in a xenograft model. 18 The concomitant treatment of SMC and TNFa can reverse the resistance in some cancer cell lines to SMC treatment alone; however, about half of the cell lines surveyed remain resistant to SMC treatment despite the addition of exogenous TNFa. 9 This resistance may limit the impact of SMCs in the clinic despite the abundance of TNFa in the tumour microenvironment. 19 Therefore, identifying the basis for SMC-resistance will benefit the application of SMCs as a cancer therapy by allowing for the rational development of treatment strategies. To gain insight into the mechanism of SMC-resistance in cancer cells, we undertook functional siRNA-based kinomic screens and identified targets that sensitize cancer cells to the SMCs AEG40730 and SM-164. On the basis of resistance to cell death in response to SMC and TNFa treatment, 9 we selected the non-small cell lung carcinoma (NSCLC) cell line H226 for the investigation of pro-survival kinases. Interestingly, we identified NF-kB-inducing kinase (NIK) as a prosurvival kinase. This pro-survival property differs from the previously suggested role of NIK as a pro-death regulator functioning to promote the production of TNFa. 16, 17 Furthermore, a siRNA screen that simultaneously targeted NIK in combination with the kinome revealed that the additional loss of suppressor of morphogenesis in genitalia-1 (SMG1) synergized with NIK knockdown to cause apoptosis upon SMC and TNFa co-treatment. We further propose that SMG1 and NIK are regulators for the metabolism of FLICE inhibitory protein (c-FLIP), a caspase-8 inhibitor. Our results show that SMG1 and NIK act as important repressors of SMC-mediated cell death possibly by sustaining the expression of c-FLIP.
Results
Functional siRNA kinome screens identified NIK and SMG1 as protective factors for SMC-mediated TNFainduced cell death. To explore factors underlying the resistance of cancer cells to SMC-mediated TNFa-induced cell death, we performed a synthetic lethal screen in which 691 kinome targets were individually knocked down before the co-treatment of SMC (AEG40730) and TNFa. To determine the effects of each knockdown on cell viability in response to the drugs, we used Alamar Blue, which measures the activity of the mitochondrial respiratory chain. 20 We previously reported that the NSCLC H226 is a SMC-resistant cell line that has an intact apoptotic pathway and the resistance of H226 cells to SMC-mediated TNFainduced cell death is reversed by c-FLIP silencing. 9 The dependency on c-FLIP allows us to assess the robustness of the assay by comparing SMC and TNFa sensitivity of H226 cells treated with c-FLIP siRNA to non-targeting siRNA. The assay offered a wide dynamic range and negligible data variability, resulting in a Z-factor of 0.59 (Figure 1a) , indicating that the kinome screen is a suitable assay for identifying bona fide hits. 21 The efficiency of siRNA targeting c-FLIP was confirmed by immunoblotting ( Figure 1b) . The siRNA kinomic library screen identified CKS2, AKT2, KHK, IKBKB, SMG1 and PIM2 as potential protective factors in SMC-mediated TNFa-induced cell death (Figure 1c) . Interestingly, the synthetic lethal kinomic screen also identified MAP3K14, which encodes for the protein NIK, as the strongest suppressor in the library (Figure 1c) .
NIK has been hinted as a component for the execution of SMC-mediated cell death, 16, 17 but here, we identify NIK as a repressor of SMC-mediated cell death. The potential duality of NIK function to inhibit or promote SMC-mediated cell death suggests that NIK function is dependent on the specific cellular context. To investigate the contribution of additional genes that might synergize with NIK-depletion in SMCmediated TNFa-induced cell death, we screened the kinomic siRNA library with NIK-depleted H226 cells. We identified NEK9, RPS6KA3, LYN, SMG1 and STK38L as genes that potentially represent secondary blocks of SMC-mediated TNFa-induced cell death in NIK-depleted H226 cells (Figure 1d ).
To determine which candidates from the NIK siRNAcoupled secondary screen were most relevant in SMCmediated cell death, we assessed protein levels of the new candidates in MDA-MB-231 cells in response to SMC treatment. The MDA-MB-231 breast carcinoma cell line responds robustly to SMC treatment ( Figure 1e ) in a manner dependent on the production of TNFa, 16 with an IC 50 of 1.32 nM by SMC-AEG40730. 9 In the presence of SMC, we found that NEK9, RPS6KA3, LYN, SMG1 and STK38L maintained their protein expression levels, but SMG1 was downregulated ( Figure 1f ). The loss of cIAP1, cIAP2 and XIAP by SMC treatment was also confirmed (Figure 1f ).
Since the loss of SMG1 coincides with the onset of SMCmediated cell death in MDA-MB-231 cells (Figures 1e and f) , we reasoned that SMG1 is likely to be a mechanistically relevant protective factor against SMC treatment. We used siRNAs from an alternative source to confirm that the dual silencing of SMG1 and NIK is more effective than single SMG1 or NIK knockdown to sensitizing H226 cells to SMCmediated TNFa-induced cell death (Figure 2a ). We next extended our assessment to NSCLC H460 and H661, which are among the most resistant cell lines to SMC treatment. 9 Similar to H226 cells, combined knockdown of NIK and SMG1 decreased viability of H460 and H661 cells that were treated with SMC and TNFa (Figure 2a ). SMG1 knockdown alone also sensitized H460 and H661 cells to SMC and TNFa treatment, while the effect of NIK knockdown was more modest (Figure 2a) .
To assess the specificity of sensitization in SMG1 and NIKdepleted cells, we analyzed the effect of SMG1 and NIK knockdown with respect to cell death caused by other apoptotic triggers, such as VP16, staurosporine and cycloheximide in combination with TNFa. We found that combined SMG1 and NIK knockdown has no effects on VP16-and staurosporine-induced cell death, but sensitizes cell death triggered by cycloheximide and TNFa treatment (Supplementary Figure 1 ). Sensitization of SMG1-and NIK-depleted cells to cycloheximide and TNFa treatment may in part be due to IAP downregulation by cycloheximide treatment. [22] [23] [24] Overall, these results suggest that NIK and SMG1 are relatively specific suppressors of SMC-mediated TNFa-induced cell death.
Depletion of SMG1 and NIK promotes SMC-mediated TNFa-induced caspase-8 activation. To determine the underlying mechanism of cell death in SMG1-and NIKdepleted cells, we assessed for caspase activity in response to SMC and TNFa treatment. Next, we analyzed the effects of caspase-8 or -9 silencing with siRNA in H226 cells that were depleted of SMG1 and NIK before SMC and TNFa treatment. Downregulation of caspase-8, but not caspase-9, prevented SMC-mediated The activation of caspases in SMG1-and NIK-depleted cells in response to SMC and TNFa treatment indicates that apoptosis might be the underlying mechanism of cell death. We next measured apoptosis using flow cytometry by identifying the percentage of cells that are stained with Figure 2 Depletion of SMG1 and NIK promotes SMC-mediated TNFa-induced caspase activation. (a) H226, H460 and H661 cells were transfected with siRNA targeting SMG1 (red bars), NIK (blue bars), both (green bars) or non-targeting (NT) siRNA (black bars) as a control. At 24 h after siRNA-mediated silencing, cells were exposed to combinations of 100 nM SMC-AEG40730 and 100 ng/ml TNFa for an additional 48 h. Cell viability was determined by Alamar Blue. Numbers represent the average ± S.E.M. of at least three assays. *Po0.01 significantly different from non-targeting siRNA and vehicle, as determined by ANOVA with post hoc Tukey's HSD. (b) H460 cells were transfected with siRNA targeting SMG1, NIK, or non-targeting siRNA as a control. At 24 h after siRNA-mediated silencing, cells were exposed to SMC for 1 h before the addition of 100 ng/ml TNFa. At the indicated times of TNFa treatment, cells were harvested and subjected to western immunoblotting with antibodies recognizing caspase-8, cleaved caspase-3, SMG1, NIK, cIAP1, cIAP2 and XIAP. b-Actin was used as a loading control. Processing of caspase-8 and -3 were detected in SMG1-and NIK-depleted cells following combined SMC and TNFa treatment. (c) H226 cells were transfected with siRNA targeting SMG1 and NIK, in combination with siRNA targeting caspase-8, -9 or RIP1 for 48 h, and then exposed to SMC and TNFa for an additional 48 h before cell viability was determined by Alamar Blue. Numbers represent the average ±S.E.M. of at least three assays. *Po0.001 significantly different from non-targeting siRNA and vehicle, as determined by ANOVA with post hoc Tukey's HSD. (d) H226 cells were treated with siRNA as in (c) for 48 h, and isolated proteins were probed by western immunoblotting for the presence of caspase-8, -9 and RIP1. The silencing of caspase-8 or RIP1 prevented SMC-mediated TNFa-induced cell death in dually NIK-and SMG1-depleted cells annexin V-fluorescein isothiocyanate (FITC) without propidium iodide uptake. Consistent with the activation of caspases, we detected increased apoptosis in response to SMC and TNFa treatment in H226, H460 and H661 cells depleted of NIK and SMG1 ( Figure 3 and Supplementary  Figure 3) . Notably, the combined downregulation of NIK and SMG1 resulted in a higher apoptotic index than single knockdowns in response to SMC and TNFa treatment ( Figure 3 and Supplementary Figure 3) . Together, these results are consistent with the ability of SMCs to induce caspase-8-mediated apoptosis upon TNFa treatment.
cIAP1, cIAP2 and XIAP cooperatively protect against TNFa-induced cell death in cancer cells depleted of SMG1 and NIK. The underlying mechanism of SMCmediated TNFa-induced cell death in cancer cells is attributed to the ability of SMCs to antagonize the cIAPs and possibly XIAP. 15,25,26. To define the contribution of each of these IAPs in blocking TNFa-induced cell death, we individually and jointly silenced cIAP1, cIAP2 and XIAP in combination with SMG1 and NIK knockdown before TNFa treatment. The combined silencing of SMG1 and NIK along with the three IAPs was sufficient to decrease H226, H460 and H661 cell viability, whereas the addition of TNFa promoted more cell death in H226 cells (Figures 4a-c) . We further demonstrated the importance of IAP antagonism by using SM-164, a different SMC that also potently targets the IAPs. 15 As expected, SM-164 treatment similarly triggered TNFa-mediated cell death in H226 cells depleted of SMG1 and NIK (Figure 4d ). In accord with results from the kinomic siRNA screens, the single knockdown of SMG1 or NIK also sensitized these IAP-deficient cancer cells to TNFa-mediated cell death (Supplementary Figures 4A-I ). Downregulation of NIK was more potent at reducing cell viability than SMG1 silencing in IAP-deficient H226 cells (Supplementary Figures  4B and C) . Conversely, SMG1 knockdown was more effective in promoting cell death than NIK downregulation in IAP-deficient H460 and H661 cells (Supplementary Figures 4E, F, H and I ). The efficiency of cIAP1, cIAP2 and XIAP knockdown by siRNA was also confirmed (Figure 4e and Supplementary Figure 5) . These results show that targeting of these three IAPs is the most effective way to induce cancer cell death in SMG1 and NIK-depleted cancer cells. , NIK or non-targeting siRNA as a control for 24 h, and then exposed to 100 nM SMC-AEG40730 for 1 h before the addition of 100 ng/ml TNFa for the indicated times. Harvested cells were processed for protein and analyzed for JNK activation by western immunoblotting. SMG1 knockdown enhances TNFa-mediated JNK activation in SMC-treated cells levels in response to SMC and TNFa treatment. We found that in SMG1-and NIK-depleted cells, c-FLIP levels decreased in response to the combined treatment of SMC and TNFa (Figure 5a ). To determine the process that regulates c-FLIP metabolism, we next screened an inhibitor library that covers a wide spectrum of proteases (Supplementary Table 1 ). We identified proteasome inhibitors gliotoxin and MG132 as the most potent blockers of c-FLIP downregulation in dually SMG1-and NIK-depleted H460 and H661 cells treated with SMC and TNFa (Figure 5b and Supplementary Figure 6 ). In addition, the proteasome inhibitor MG262 similarly prevented c-FLIP degradation (Figure 5b ). These results indicate that the proteasome has a major role in SMC-mediated c-FLIP turnover triggered by TNFa.
JNK-mediated activation of the ubiquitin-proteasome pathway can facilitate the downregulation of c-FLIP. 27 We have previously shown that in cancer cell lines resistant to SMC treatment, JNK activation is repressed in response to TNFa. 9 In contrast, SMC treatment activates the JNK pathway in MDA-MB-231 cells, a SMC-sensitive cell line (Figure 5c ). We therefore examined for the activation of JNK in response to SMC and TNFa treatment in SMG1-and NIKdepleted cells. In H460 and H661 cells treated with SMC, silencing of SMG1, but not NIK, led to increased TNFamediated activation of JNK1, JNK2 and JNK3 (Figure 5d ). Together, these data suggest that SMG1 represses JNK activity and prevents c-FLIP degradation by the proteasome in response to SMC and TNFa treatment.
Upregulation of NIK by SMC treatment activates both the classical and alternative NF-jB pathways and enhanced c-FLIP transcription. As NIK did not regulate c-FLIP levels via the JNK pathway, we next investigated the possibility that NIK, as a modulator of nuclear factor-kB (NF-kB) pathway, might regulate c-FLIP transcription. Activation of alternative NF-kB pathway requires the processing of phosphorylatedp100 to produce p52. 28 Phosphorylation of p100 can be either directly catalyzed by NIK or indirectly via IKKa dimers. 28 Furthermore, activated NIK can cross-talk with the classical NFkB pathway through the NIK-IKK complex. 29 In response to SMC treatment, NIK protein levels accumulated in H226, H460 and H661 cells ( Figure 2B and Supplementary Figure 2) , thereby promoting the production of p52 (Figures 6a and c) . As expected, when NIK was silenced by siRNA, production of p52 decreased in response to SMC treatment (Figures 6a and c) . Downregulation of SMG1 showed no effect on either NIK levels or p52 production (Figures 2b, 6a and c, Supplementary  Figure 2) . Moreover, SMC treatment promoted persistent phosphorylation of p65, indicating that the classical NF-kB pathway was also activated (Figure 6c) . Silencing of NIK, but not SMG1, repressed SMC-mediated phosphorylation of p65 ( Figure 6c ). As the increase in NF-kB activity may modulate c-FLIP transcription, 30 we next assessed for c-FLIP mRNA levels after SMC and TNFa treatment. In H226 cells, c-FLIP mRNA levels markedly increased in response to SMC and TNFa treatment (Figure 6b) . Knockdown of NIK, but not SMG1, blocked the increase in c-FLIP mRNA levels (Figure 6b) . Similarly, NIK knockdown reduced c-FLIP messages in H460 and H661 cells treated with SMC and TNFa (Supplementary Figure 7) . Therefore, these results indicate that NIK upregulation by SMC treatment activates both the classical and alternative NF-kB pathways and may maintain c-FLIP levels by enhancing the amount of c-FLIP transcripts.
Downregulation of IAPs and c-FLIP leads to cancer cell death. Silencing of endogenous SMG1 and NIK sensitizes cancer cells to SMC-mediated TNFa-induced cell death (Figures 1-3 and Supplementary Figure 3) . Similarly, siRNAmediated downregulation of SMG1 and NIK in combination with IAP silencing also promoted cell death (Figure 4 and Supplementary Figure 4) . The ability of SMG1 and NIK to maintain TNFa-regulated c-FLIP levels in response to SMC (Figures 7b and c) . Remarkably, the knockdown of XIAP and c-FLIP in H460 cells induced significant cell death (Figure 7b) . Together, these results show that endogenous IAPs and c-FLIP are crucial in maintaining cancer cell viability.
Discussion
SMG1 and NIK are novel repressors of SMC-mediated TNFa-induced apoptosis. SMCs are rationally designed small molecules for cancer therapies that target the IAPs. The ability of SMCs to induce TNFa-dependent cell death depends on the molecular signature of the cancer cell. 9 Although the basic components necessary for the execution of cell death by SMCs are relatively well-defined, the underlying molecular pathways involved in SMCresistance in the presence of exogenous TNFa remain poorly understood. Here, we utilized a functional siRNA kinomic screen to identify factors involved in SMCresistance. We show that the protein kinases NIK and SMG1 have important roles in protecting cancer cells from SMC-mediated TNFa-induced apoptosis, likely through sustaining expression levels of c-FLIP that corresponds to the long isoform. 31 Specifically, SMG1 may maintain c-FLIP levels by repressing JNK activation that consequently prevents proteasomal degradation of c-FLIP, whereas NIK may maintain transcriptional levels of c-FLIP mRNA by activating both the classical and alternative NF-kB pathways (Figure 8 ).
The dual role of NIK in SMC-mediated apoptosis. The identification of NIK as a protective factor in SMC-mediated TNFa-induced apoptosis underscores the duality of the NF-kB pathway. The loss of cIAP1 and cIAP2 by SMC treatment allows for the accumulation of NIK, 16 ,17,32 a critical regulator that activates the alternative NF-kB pathway, but also cross-talks to activate the classical NF-kB pathway. 29 In SMC-sensitive cell lines, activation of the NF-kB pathways upregulates TNFa levels, 16, 17 which acts in an autocrine manner to facilitate SMC-mediated apoptosis. 18 By comparison, our current findings show that in SMCresistant cell lines, NIK is pro-survival and can activate NF-kB pathways that may sustain c-FLIP expression. The consequence of persistent c-FLIP expression is the suppression of apoptosis, as c-FLIP inhibits caspase-8 to block the progression of cell death. 33, 34 Hence, the role for NIK in SMC-mediated cell death reflects the reliance of cancer cells on both NF-kB pathways for the balance between survival and death.
SMG1 and c-FLIP are potential biomarkers for SMC responsiveness. Our studies also identified SMG1 as another repressor of SMC-mediated TNFa-induced apoptosis. SMG1 has been previously linked to diverse cellular responses including oxidative stress, hypoxia, TNFamediated signalling, and mRNA surveillance mechanisms regulating nonsense-mediated mRNA decay. [35] [36] [37] [38] We propose that a connection exists between SMG1 and c-FLIP turnover through the JNK signalling pathway. Notably, we previously reported that in SMC-resistant cells, TNFa-mediated activation of JNK is repressed following SMC treatment. 9 In contrast, knockdown of SMG1 in SMCresistant cells allows downstream JNK signalling to proceed. Activated JNK can in turn phosphorylate ITCH, an ubiquitin E3 ligase that has been linked to facilitate c-FLIP turnover in a proteasome-dependent manner, 27 ,39 a property that is consistent with our observation that c-FLIP metabolism is blocked by proteasome inhibitors. Furthermore, we found that SMC-induced loss of SMG1 in SMC-sensitive MDA-MB-231 cells is correlated with prolonged JNK activation and c-FLIP downregulation. Given these observations, we propose that the downregulation of SMG1 and c-FLIP might serve as functional biomarkers for SMC responsiveness.
Targeting IAPs and c-FLIP: implications for cancer therapy. Our results raise the prospect of addressing the potential obstacles faced with IAP-targeting strategies in cancer therapies. Notably, the combined knockdown of XIAP and c-FLIP was sufficient to cause marked cell death in NSCLC H460 and H661, even in the absence of exogenous TNFa, suggesting a heightened reliance on XIAP and c-FLIP for survival in certain cancer cells. 40 Moreover, SMC-induced apoptosis and MDA-MB-231 xenograft tumour regression were found to be the most effective when SMCs potently target cIAP1, cIAP2 and XIAP concurrently. 15 Overall, these results imply that the combination of a pan-IAP SMC and c-FLIP silencing would maximize cancer cell death.
The deciphering of SMC mode of action will have significant implications on the applicability of SMCs as an emerging cancer therapeutic. Our strategy demonstrates the power of coupling functional siRNA and focused chemical screens with a rational targeted approach to investigate the underlying mechanism of biological processes. We have previously established that the silencing of c-FLIP by siRNA reverses SMC-resistance in a broad range of cancer cell lines to extrinsic apoptosis triggers such as TNFa and TRAIL. 9 We now show that NIK and SMG1 are potential regulators of c-FLIP level at distinct points in SMC-resistant cancer cells. These findings provide novel insight into the complex mechanism of SMC-mediated apoptosis and identify NIK and SMG1 as candidate therapeutic targets for SMC sensitization. Cell culture. MDA-MB-231 breast carcinoma, NCI-H226 (H226), NCI-H460 (H460) and NCI-H661 (H661) cells were obtained from ATCC (Manassas, VA, USA) and maintained at 37 1C and 5% CO 2 in DMEM media supplemented with 10% heat-inactivated fetal calf serum, penicillin, streptomycin and 1% non-essential amino acids (all from Invitrogen, Burlington, ON, Canada).
Functional siRNA-based synthetic lethal screen validation. For the development of a functional siRNA-based synthetic lethal screen that would identify protective factors against SMC treatment, H226 cells were selected because of their strong resistance toward SMC-mediated TNFa-induced cell death. 9. siRNA targeting c-FLIP was used as a positive control as c-FLIP has been previously identified as a protective factor against SMC treatment.
9 siRNA targeting c-FLIP (Dharmacon ON-TARGETplus SMARTpool, Lafayette, CO, USA) and non-targeting siRNA (Dharmacon Accell) were printed to 384-well plates in a checkered pattern. H226 cells were reversed transfected with 10 nM siRNA using DharmaFECT I (Dharmacon) for 24 h, followed by treatment of 100 nM SMC-AEG40730 and 100 ng/ml TNFa for an additional 48 h. Cell viability was determined by resazurin/ Alamar Blue vital dye (Sigma-Aldrich) that measures mitochondrial metabolic activity. 20 The results were analyzed to determine the two extremes of activity range and robustness of the screening assay. The screening window coefficient, or Z-factor, was determined as followed:
A Z-factor 40.5 represented an excellent assay suitable for high-throughput screening.
Kinome siRNA screening. A human kinome library containing 691 siRNAs targeting genes that encode for protein kinases, lipid kinases, carbohydrate kinases and regulatory subunits was obtained from Qiagen (Mississauga, ON, Canada). Each siRNA duplex from the kinome library was printed to 384-well plates that also contained designated wells with siRNA targeting c-FLIP or non-targeting siRNA. H226 cells were reversed transfected with 10 nM siRNA using DharmaFECT I. At 24 h post-transfection, cells in paired plates were treated with either vehicle or 100 nM SMC-AEG40730 and 100 ng/ml TNFa. At 48 h post-drug exposure, cell viability was assessed by Alamar Blue, and the percentage viability was calculated as the ratio of siRNA treatment in the presence of drugs to vehicle treatment. Singly synthetic lethal siRNAs (o50% viability) were excluded from further analysis. For the NIK-siRNA-coupled screen, cells were transfected with 2 nM siRNA targeting NIK in addition to the individual genes in the library. At 24 h post-transfection, cells were treated with SMC-AEG40730 and TNFa for an additional 48 h and cell viability was determined. Additional siRNAs targeting SMG1, NIK, cIAP1, cIAP2, XIAP, caspase-8, -9 and RIP1 were obtained from Dharmacon (ON-TARGETplus SMARTpool). A nontargeting pool siRNA control (Dharmacon) was used as an RNA interference control for all siRNA transfections.
Western immunoblotting. Cells were collected by centrifugation and lysed in 50 mM Tris-HCl, pH 8.0. containing 1% Triton X-100, 150 mM NaCl, 1 mM NaF, 0.1 mM phenylmethylsulfonyl fluoride, 5 mg/ml pepstatin A and 10 mg/ml each of leupeptin and aprotinin (lysis buffer) and insoluble materials were pelleted by centrifugation at 12 000 Â g for 30 min at 4 1C. Supernatants were collected for protein determination by Bio-Rad (Mississauga, ON, Canada) Protein Assay using bovine serum albumin as a standard. Samples were solubilized with sample buffer (62.5 mM Tris-HCl, pH 6.8 containing 2% SDS, 1% b-mercaptoethanol and 5% glycerol), and equal amounts of samples were separated on polyacrylamide gels followed by transferred to nitrocellulose. Following protein transfer, individual proteins were detected by western immunoblotting using the following antibodies recognizing: b-actin (clone AC-15) from Sigma; cleaved caspase-3 (9661), caspase-9 (9502), JNK (9252), phospho(T183/Y185)-JNK (9251), Lyn (clone 5G2), NIK (4994), p100/p52 (4882), p65 (clone C22B4), phosphor(S536)-p65 (clone 93H1) and SMG1 (4993, 9592) from Cell Signaling Technology (Danvers, MA, USA); caspase-8 (AHZ0502) from Invitrogen; c-FLIP (clone NF6) from Alexis Biochemicals (Lausen, Switzerland); RPS6KA3 (TA303691) from Origene (Rockville, MD, USA); NEK9 (ab71812) and STK38 L (ab84873) from Abcam (Cambridge, MA, USA); and RIP1 (clone 38) from BD Biosciences (Franklin Lakes, NJ, USA). Our rabbit anti-rat IAP1 and IAP3 polyclonal antibodies were used to detect cIAP1/2 and XIAP, respectively. 7 Bound primary antibodies were reacted with secondary antibodies conjugated to AlexaFluor680 (Invitrogen) or IRDye800 (Rockland, Gilbertsville, PA, USA) and the infrared fluorescent signals were detected using the Odyssey Infrared Imaging System (LI-COR).
Apoptosis assay. siRNA-targeted and drug-treated cells were used to determine the translocation of phosphatidylserine from the inner to the outer surface of the plasma membrane during apoptosis by using the human phospholipid-binding protein, annexin V, conjugated to FITC, as according to the manufacturer's instructions (BD Biosciences). The percentage of apoptotic (annexin V-positive and propidium iodide-negative) cells was determined by flow cytometric analysis (BD Biosciences Immunocytometry Systems BD FACSDiva and De Novo FCS Express V3).
Quantitative reverse transcription-PCR. To measure relative mRNA expression levels, total RNA was isolated from cells after siRNA and drug treatments (RNeasy Mini Kit, Qiagen). One step quantitative reverse transcription-PCR was performed using the QuantiTect SYBRGreen RT-PCR kit (Qiagen) with 100 ng total RNA with validated gene-specific QuantiTect Primers (c-FLIP: QT00064554; GAPDH: QT01192646; b-actin: QT01680476) on an Eppendorf Mastercycler ep realplex. No genomic DNA amplification was seen with controls that lack the reverse transcription step (i.e., 410 cycle difference compared with complete protocol).
Statistical analysis. Statistical comparisons were performed using ANOVA with post hoc Tukey's HSD.
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